TMS Co., Ltd.

TMS Co., Ltd. is involved in the research, development, manufacture, and sale of pharmaceuticals, quasi-drugs, drug substances, medical devices, and medical commodities. The company is developing TMS-007, a stachybotrys microspora triprenyl phenol (SMTP) congener with prothrombolytic and anti-inflammatory/antioxidative activities, which has completed Phase 2a clinical trials for acute ischemic stroke treatment. It is also developing TMS-008, an SMTP congener with anti-inflammatory/antioxidative activities, in nonclinical development for inflammatory complications such as acute kidney injury and cancer cachexia, and TMS-009, a product candidate in preclinical development. Additionally, TMS collaborates with Hokkaido University to evaluate the potential of its drug candidate compounds as novel drugs. Incorporated in 2005, the company is headquartered in Fuchu, Japan.